Berkshire Trims DaVita Stake, Doubles Down on Bending Spoons as UBS Lifts Target to $628
Published on 10/30/2026 at 03:21 | Editorial boerse-global.de
Berkshire Hathaway has been moving capital on two fronts at once, trimming an older healthcare bet while deepening a newer technology one. The conglomerate sold part of its DaVita holding back to the dialysis provider, raising roughly $69 million, according to Reuters. What remains is a 45% stake, or about 28.31 million shares — a position large enough that the transaction reads as a partial monetization rather than an exit.
That distinction matters for anyone trying to parse Berkshire's intentions. The sale generates cash and leaves a substantial interest intact; it does not, on its own, signal a broader retreat from DaVita. The size of the retained stake carries as much interpretive weight as the proceeds themselves.
Two Moves, Two Directions
Running alongside the DaVita sale is a fresh commitment to Bending Spoons. As the Financial Times reported, Berkshire closed another private placement totaling $330 million, with Bending Spoons issuing ten million ordinary shares at $33.00 apiece. The transaction lifts Berkshire's stake in the software company to 4%.
Should investors sell immediately? Or is it worth buying Berkshire Hathaway?
The two deals point in opposite directions — a reduced position at DaVita, an enlarged one at Bending Spoons — but drawing a direct line between them would be a stretch. Treating the DaVita proceeds as earmarked financing for the Bending Spoons investment would be premature. The placement builds on an existing holding rather than opening a new one: Berkshire had already put $600 million into Bending Spoons at its July 2026 IPO, bringing the total commitment to $930 million, per company statements. Bending Spoons said the investment supports its acquisition strategy.
UBS Raises Its Sights
On October 22, UBS analyst Brian Meredith lifted his price target on Berkshire's B-class shares to $628 from $604, reaffirming a buy rating. The upgrade landed during a stretch when investors were favoring defensive, cash-rich companies. Media reports attributed Berkshire's recent share-price strength to a rotation away from technology stocks rather than to any fresh corporate announcement — a market-driven explanation that sits apart from UBS's assessment. The higher target reflects the bank's positive view; it is not evidence that operating earnings have already improved.
The November 6 Reckoning
Both threads converge on the same date. Berkshire is expected to report third-quarter 2026 results before the market opens on November 6, giving investors a concrete occasion to test the raised expectations against actual numbers.
Until then, the picture splits into separate layers. The defensive positioning helps explain the friendlier trading environment, while the quarterly report can speak to how the business itself is performing. The DaVita sale and the Bending Spoons build-up document real changes to individual holdings, yet neither is sufficient to infer a sweeping strategic reset. The announced reporting date is a potential catalyst ahead — not the reason behind the rally that has already happened. For now, UBS's more optimistic valuation faces off against a market-rotation account of recent strength, with the September-quarter figures set to settle the question.
Ad
Berkshire Hathaway Stock: New Analysis - 30 October
Fresh Berkshire Hathaway information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
